Veracyte, Inc. cash flow to debt ratio of 343.74% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Veracyte, Inc.'s free cash flow has increased 98.45% from $63.81M last year to $126.63M, signaling increasing performance

Veracyte, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Veracyte, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.03 today, signaling strengthened financials

Veracyte, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Veracyte, Inc.'s latest filing, so interest coverage cannot be calculated.

Veracyte, Inc.'s profit margin has increased (276.26%) in the last year from 5.41% to 20.37%, signaling increasing performance

Veracyte, Inc.'s short-term assets of $488.38M exceed its short-term liabilities of $59.94M

Veracyte, Inc.'s return on assets of 7.70% is higher than the 5.00% threshold, indicating efficient asset utilization

Veracyte, Inc.'s return on equity of 8.64%, is lower than 15.00%, indicating bad performance

Veracyte, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Veracyte, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Veracyte, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Veracyte, Inc. has a free cash flow yield of 3.43%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Veracyte, Inc.'s yearly earnings has increased 174.89% since last year from $24.14M to $66.35M, signaling increasing performance

Veracyte, Inc.'s yearly revenue has increased 16.01% since last year from $445.76M to $517.14M, signaling increasing performance

ROIC 6.70% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Veracyte, Inc.'s 3-year revenue CAGR of 20.37% is positive, indicating growing revenue over the past 3 years

Veracyte, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Veracyte, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Veracyte, Inc. has insufficient data to evaluate this check.

Veracyte, Inc. has an earnings yield of 3.11%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Veracyte, Inc. is overvalued relative to its fair value price of 11.96 based on EBITDA multiple model

Veracyte, Inc. has an EV/EBITDA ratio of 37.03x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Veracyte, Inc. is overvalued relative to its fair value price of -17.21 based on Earnings Fair Value model

Veracyte, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Veracyte, Inc. has a price-to-book ratio of 2.65x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Veracyte, Inc. has a price-to-sales ratio of 6.56x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue